The experimental cancer drug ibrutinib has wowed in clinical trials, beating deadly blood cancers without the painful side effects of currently approved therapies. And it has raced through development and regulatory hurdles, in part thanks to a US program to accelerate the development of particularly promising drugs, says its developer Pharmacyclics, based in Sunnyvale, California.
Image Courtesy of renjith krishnan / FreeDigitalPhotos.net
